Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Lilly's oral GLP-1 charts 10.5% weight loss in diabetic patients
With another orforglipron trial already in the books, Lilly has unveiled the rest of the data underpinning the med's obesity approval bid.
Fraiser Kansteiner
Aug 26, 2025 6:45am
ProKidney cell therapy wins half of trial, falls short on other
Jul 8, 2025 8:00am
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
Jun 23, 2025 2:30pm
Biolinq raises $100M to carry glucose sensor patch to the FDA
Apr 22, 2025 12:00pm
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
Apr 17, 2025 6:45am
Dexcom survey shows providers opt for tech over drugs in Type 2
Mar 19, 2025 12:20pm
